ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

31214 results sorted by trial registration date.
  • Placebo controlled, double-blind study for efficacy of two herbal supplements (Trigonella foenum-graecum Seed Extract and Coccinia Grandis Extract) for Normalizing Elevated (pre-diabetic) blood Glucose and improving Insulin Sensitivity - a 3 arm study.

    The aim of this study is to assess the efficacy of Trigonella foenum-graecum (Fenugreek) Seed Extract and Coccinia indica in reducing elevated normal blood glucose levels through reducing insulin levels (B-cell function) and reducing insulin resistance (blood glucose) in pre-diabetics. In addition, other parameters associated with altered metabolism that contribute to the development of diabetes, HBa1c, lipid studies, body weight will also be assessed.

  • Pilot experimental study for safety and efficacy of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) in reducing symptoms of Seasonal Allergic Rhinitis.

    The aim of the study is to use of an intranasal spray containing of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) to determine if it is superior to placebo in reducing the severity of the symptoms of seasonal allergic rhinitis (SAR) over 7 days.

  • The success of research implementation strategies on evidence informed decision making by allied health managers: a randomised controlled trial

    This study aims to improve the translation of research evidence into healthcare practice. We will achieve this aim by comparing two different strategies to help allied health managers make resource allocation decisions in the hospital setting. One group will be provided with an "evidence-based policy recommendation" document; the other group will be provided with the same document with the addition of an expert knowledge broker to assist in the decision-making process; A third "control" group will not be provided with either of the interventions during the study period. The success of these research implementation strategies will be measured by comparing between group changes in practice to align with the policy recommendations. We will also explore the (1) opportunity cost to make decision (time to make decision, resources used, and knowledge broker time attributable to each participant in implementation strategy group 2); (2) participant perceptions of the research evidence related to this issue; (3) sources of evidence relied upon during decision-making; (4) domains of decision making that were most influential upon the decision to adopt the policy or not; (5) average hospital length of stay at baseline and 12-months; and (6) suggested improvements, perception of risk, and barriers and facilitators encountered in adopting or not adopting the policy recommendation.

  • A phase 2, open label trial of guadecitabine (SGI-110) in patients with T-cell lymphoma

    The purpose of this study is to test the safety, tolerability and anti-tumour activity of the research study drug, guadecitabine. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with T-cell non-Hodgkin lymphoma, which has (a) not been treated, (b) been deemed unsuitable for standard therapy or (c) have relapsed or refractory disease. Study details All participants will receive subcutaneous injections of guadecitabine for the first 5 days of a 28 day treatment cycle. Treatments will be given for at least 6 of these 28 day cycles. This is a safety and efficacy trial, so any adverse events will be recorded and the effect of the study treatment on the lymphoma will be monitored using a PET or CT scan. This study will provide information about this study drug and allow subsequent study of this potential treatment for T-cell non-Hodgkin lymphoma.

  • Optimising care: a program supporting women with metastatic breast cancer to be active and eat well

    The aim of this study is to assess the feasibility and safety of an individually-tailored exercise and dietary program for women with metastatic breast cancer (MBC) and provide preliminary evidence on changes in patient-relevant outcomes such as quality of life. Who is it for? You may be eligible to join this study if you are a woman aged 18 years or over and have a diagnosis of metastatic breast cancer in the previous 5 years, or progression of metastatic disease over the last 2 years. Study details All women will receive a 16-week exercise and dietary program, individually-tailored based on their baseline assessment, tumour burden and treatment. The program will focus on increasing exercise (aerobic- and resistance-based), improving diet quality and managing nutritional symptoms (e.g., nausea/vomiting, constipation/diarrhoea), to improve (or attenuate declines in) quality of life, lean body mass and physical function. Data will be collected at baseline (T1/pre-intervention), 16-weeks (T2/end-of-intervention) and 10-months (T3/six-months post-intervention). We hypothesise that a 16-week exercise and dietary program will be feasible and safe for women with MBC and will improve (or reduce declines in) patient-relevant outcomes.

  • Negative Pressure Dressing in Pilonidal Surgery

    This is a prospective, randomised controlled trial comparing SNAP dressings, a type of negative-pressure wound therapy dressing, with standard wound dressings for patients aged 12-40 years undergoing an excision of a pilonidal sinus. Eligible patients (and for paediatric patients, their parents/guardians) will be approached for enrolment. Participants will then be randomised to have a SNAP dressing or standard wound dressing placed on the surgical wound after the pilonidal sinus has been excised and the wound primarily closed. Post-operatively, patients will be followed up on days 3, 7, 10 and 14 and then weekly in the Outpatients Clinic until the wound has healed to examine the wound. Follow-up will be conducted by a clinical nurse specialist or other member of the treating team. There will also be a follow-up 2 months and 6 months post-operatively. The study and patient follow-up will be assessing: 1. Rate of wound dehiscence (breakdown) in each group and assessment of progression of wound dehiscence using clinical photographs as evaluated by a blinded outcome assessor (clinical photographs only taken for wounds where a dehiscence has occurred) 2. Time taken for the wound to fully heal 3. Rate of disease recurrence within 6 months post-operatively 4. Analgesia requirements for the wound 5. Ratio of wound size two weeks post-operatively compared to at the time of surgery 6. Patient satisfaction with the dressing and wound healing and quality of life survey 2 months post-operatively 7. Patient phone/email questionnaire regarding disease recurrence and progress 6 months post-operatively 8. Time taken to resume normal activities For patients randomised to have a standard dressing (i.e. no SNAP dressing) who have a wound dehiscence, the endpoint for this trial would have met. For these patients, some will receive a SNAP dressing as determined by the treating team for further management of the dehisced wound. We will compare wound healing and assess outcomes in these patients with patients who go on to have further management with a standard dressing. This study will thus be aiming to establish whether the use of a negative wound pressure therapy dressing (SNAP dressing) improves wound healing, the rate of wound dehiscence, recurrence rates and patients’ quality of life and return to normal activities compared to a standard wound dressing.

  • Effects of electrical stimulation and tendon vibration on muscle force in people with spinal cord injury

    Ten subjects with SCI already involved in an activity-based exercise/rehabilitation program visited the Neuromuscular Physiology laboratory at Edith Cowan University on three occasions at the same time of day separated at least by 72 h. The experimental conditions were only be two in this Study 2. The first session was a familiarisation session and the following two were experimental sessions with conditions completed in a randomised order. The aim of this study was to replicate the most efficient NMES protocol found in Study 1 in healthy population to provide the greatest total impulse and lowest fatigue rate, imposed both with and without simultaneous tendon vibration, to investigate acute effects in people with SCI. Electrical stimulation protocol Participants sat on a test chair and will be given twitches of electrical stimulation of the thigh muscle while their leg was held stationary by a testing machine (isokinetic dynamometer). Two passive electrodes were placed on the skin over their stronger thigh muscle (quadriceps) and they were given one of the electrical stimulation protocols. All of these procedures were safe, and are commonly performed at Edith Cowan University. The purpose of the present study was to determine whether patellar tendon vibration superimposed onto wide-pulse width NMES under standard clinical conditions elicits a greater peak muscle force with less muscle fatigue (i.e. a greater total impulse) when compared to NMES applied without patellar tendon vibration in people with SCI. We hypothesised that patellar tendon vibration superimposed onto wide-pulse width NMES would elicit a greater peak muscle force with less muscle fatigue (i.e. a greater total impulse) that NMES applied without patellar tendon vibration in people with SCI.

  • The anti-anginal effect of Zibotentan in the Coronary Slow Flow Phenomenon (CSFP)

    The coronary slow flow phenomenon (CSFP) is a coronary microvascular disorder that was first clinically characterised by University of Adelaide researchers. It is defined using a coronary angiography, a x- ray like procedure where a dye is injected into the heart arteries to investigate the patency of arteries, by delayed dye opacification of the large heart arteries, reflecting the underlying increased microvascular (small arteries) resistance. Studies conducted both at the University and at other sites, have implicated Endothelin-1 (a potent microvascular vasoconstrictor) could explain the CSFP. Basing on the existing evidence, present study investigates, Zibotentan, a potent endothelin-1 receptor blocker, benefits the CSFP patients by reducing angina frequency using a randomized, double-blind, placebo-controlled, cross-over trial design.

  • A clinical trial for the assessment of effect of oral ibuprofen drug on the outcome post repair of hand flexor tendons

    Title: A double blind randomised controlled trial assessing the effect of oral ibuprofen on outcome of flexor tendon repairs Short Title: Ibuprofen Flexor Tendon Trial (IFTT) Design: Double Blind Randomised Controlled Trial Hospital/s: Gold Coast Hospital and Health Service Study Question: Does oral ibuprofen influence outcome in patients post flexor tendon repair? Primary purpose of the study: This study has been designed to assess the effect of using oral ibuprofen after repair of hand flexor tendons on function and final outcome of hand . Study hypothesis is that use of oral ibuprofen after flexor tendon repair will result in improved outcome in comparison to when ibuprofen is not given.Ibuprofen should also result in decreased swelling of fingers. Many work hours will be saved and quality of life will be improved in flexor tendon repair patients if the study hypothesis is found to be true and a cheap and easily available drug like ibuprofen can reduce financial burden of these injuries on society and community. Study Objectives: Primary Objectives: Assessment of the effect of oral ibuprofen on outcome of flexor tendon repairs in humans: 1) Range of motion assessment using Strickland criteria 2) Range of motion assessment using ASSH criteria 3) Grip strength assessment 4) Michigan Hand Outcomes Questionnaire for evaluation of hand outcome Secondary Objectives: 1) Assessment of finger circumference 2)Assessment for delayed wound healing 3) Assessment for rupture of tendons 4) Assessment of need for tenolysis or follow up surgeries. Inclusion Criteria: 18 years of age and above Exclusion Criteria: Contraindication to NSAIDs/ibuprofen, systemic conditions/diseases like cardiac, renal, CNS, GI and others, documented allergy to NSAIDs Number of Planned Subjects: 66 Investigational product: Oral Ibuprofen Safety considerations: Coexisting cardiovascular, gastrointestinal and renal diseases; certain drugs Statistical Methods: Two arm trial- interventional and control. Two-sample t-test for a type 1 error (alpha) of 0.05 and a power of 90% for sample size calculation.

  • Electrical stimulation-muscle strength training in people with spinal cord injury

    Background: Muscle force production is usually impaired in people with spinal cord injury (SCI). However, the use of high-intensity NMES strength training can help promote metabolically active lean muscle mass and thus, increase muscle mass and provide physical health and quality of life (QoL) benefits. Nonetheless, NMES is usually used at low-stimulation intensities (e.g. functional electrical stimulation) and there is limited evidence regarding the effects of high-intensity NMES strength training for increasing muscle force capacity and mass, ameliorating symptoms of spasticity or improving physical health markers and quality of life (QoL) in people with SCI. The primary purpose of this study was to investigate the effects of electrical stimulation of the thigh muscles using pads into improving the muscle size, muscle force, physical health, symptoms of spasms in the muscles and well-being in people who suffered from an accident and their legs are paralysed. The study hypotheses was that 12-weeks of electrical stimulation used as a muscle strength tool will improve muscle mass, muscle size, physical health, symptoms of spasms in the muscles and well-being in people who suffered from an accident and their legs are paralysed. Methods: Five individuals with SCI completed five 10-repetition sets of high-intensity isometric knee extension NMES strength training sessions for 12 weeks in both right (R) and left (L) quadriceps muscles. Quadriceps femoris isometric knee extensor torque was measured on a dynamometer and cross-sectional area (CSA- quadriceps femoris (QF)) were measured with extended-field-of-view ultrasonography. Venous blood samples were collected for blood lipid profiling and c-reactive protein (CRP) analyses. The Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) was used to assess symptoms of spasticity and the quality of life index (QLI) SCI version III was used for QoL measures.

Tags:
  • Finding clinical trials